O	0	2	An
O	3	7	open
O	7	8	-
O	8	13	label
O	13	14	,
O	15	25	randomized
O	25	26	,
O	27	38	multicenter
O	39	43	dose
O	43	44	-
O	44	51	finding
O	52	57	study
O	58	60	of
O	61	65	once
O	65	66	-
O	66	69	per
O	69	70	-
O	70	75	cycle
B-intervention	76	89	pegfilgrastim
O	90	96	versus
O	97	102	daily
B-control	103	113	filgrastim
O	114	116	in
B-ethinicity	117	124	Chinese
B-eligibility	125	131	breast
I-eligibility	132	138	cancer
I-eligibility	139	147	patients
I-eligibility	148	157	receiving
I-eligibility	158	161	TAC
I-eligibility	162	174	chemotherapy
O	174	175	.

O	176	177	A
O	178	190	chemotherapy
O	191	198	regimen
O	199	201	of
O	202	211	docetaxel
O	211	212	,
O	213	224	doxorubicin
O	225	228	and
O	229	245	cyclophosphamide
O	246	247	(
O	247	250	TAC
O	250	251	)
O	252	255	has
O	256	260	been
O	261	269	accepted
O	270	272	as
O	273	274	a
O	275	283	standard
O	284	288	care
O	289	296	because
O	297	299	of
O	300	305	their
O	306	314	superior
O	315	323	clinical
O	324	331	benefit
O	332	334	in
O	335	340	early
O	340	341	-
O	341	346	stage
O	347	353	breast
O	354	360	cancer
O	361	369	patients
O	369	370	,
O	371	374	but
O	375	379	with
O	380	381	a
O	382	388	higher
O	389	393	risk
O	394	396	of
O	397	408	neutropenia
O	408	409	.

O	410	423	Pegfilgrastim
O	424	426	is
O	427	428	a
O	429	433	once
O	433	434	-
O	434	437	per
O	437	438	-
O	438	443	cycle
O	444	451	therapy
O	452	455	for
O	456	468	prophylactic
O	469	479	neutrophil
O	480	487	support
O	488	491	and
O	492	503	neutropenia
O	504	514	prevention
O	514	515	.

O	516	521	There
O	522	525	was
O	526	531	still
O	532	533	a
O	534	538	lack
O	539	541	of
O	542	548	direct
O	549	558	evidences
O	559	562	for
O	563	570	finding
O	571	573	an
O	574	581	optimal
O	582	587	fixed
O	588	592	dose
O	593	595	of
O	596	609	pegfilgrastim
O	610	612	in
O	613	620	Chinese
O	621	627	breast
O	628	634	cancer
O	635	643	patients
O	644	653	receiving
O	654	657	TAC
O	658	665	regimen
O	665	666	.

O	667	669	An
O	670	674	open
O	674	675	-
O	675	680	label
O	680	681	,
O	682	692	randomized
O	692	693	,
O	694	699	phase
O	700	702	II
O	703	708	study
O	709	712	was
O	713	721	designed
O	722	724	to
O	725	732	compare
O	733	736	the
O	737	744	effects
O	745	747	of
O	748	761	pegfilgrastim
O	762	766	with
O	767	777	filgrastim
O	777	778	.

O	779	787	Eighteen
O	788	795	centers
O	796	798	in
B-location	799	804	China
O	805	813	enrolled
B-total-participants	814	817	171
O	818	826	eligible
O	827	833	female
O	834	840	breast
O	841	847	cancer
O	848	856	patients
O	857	861	with
O	862	868	cycles
O	869	871	of
O	872	875	TAC
O	876	888	chemotherapy
O	889	898	treatment
O	898	899	,
O	900	910	randomized
O	911	915	into
O	916	920	four
O	921	925	arms
O	925	926	,
O	927	935	received
O	936	937	a
O	938	944	single
O	945	957	subcutaneous
O	958	967	injection
O	968	970	of
O	971	984	pegfilgrastim
O	985	986	(
O	986	988	60
O	988	989	,
O	990	993	100
O	994	996	or
O	997	1000	120
O	1001	1002	µ
O	1002	1003	g
O	1003	1004	/
O	1004	1006	kg
O	1006	1007	)
O	1008	1011	per
O	1012	1024	chemotherapy
O	1025	1030	cycle
O	1031	1033	or
O	1034	1039	daily
O	1040	1052	subcutaneous
O	1053	1063	injections
O	1064	1066	of
O	1067	1077	filgrastim
O	1078	1079	5
O	1080	1081	µ
O	1081	1082	g
O	1082	1083	/
O	1083	1085	kg
O	1086	1088	24
O	1089	1090	h
O	1091	1096	after
O	1097	1109	chemotherapy
O	1109	1110	.

O	1111	1119	Efficacy
O	1120	1123	and
O	1124	1130	safety
O	1131	1135	were
O	1136	1144	analyzed
O	1144	1145	.

O	1146	1148	In
O	1149	1152	ITT
O	1153	1163	population
O	1163	1164	,
O	1165	1168	the
B-outcome	1169	1173	mean
I-outcome	1174	1182	duration
I-outcome	1183	1185	of
I-outcome	1186	1191	grade
I-outcome	1192	1193	3
I-outcome	1193	1194	+
I-outcome	1195	1206	neutropenia
O	1207	1208	(
O	1208	1218	neutrophil
O	1219	1224	count
O	1225	1226	<
O	1226	1227	1
O	1227	1228	.
O	1228	1229	0
O	1230	1231	×
O	1232	1234	10
O	1234	1235	(
O	1235	1236	9
O	1236	1237	)
O	1237	1238	/
O	1238	1239	l
O	1239	1240	)
O	1241	1244	was
B-iv-cont-mean	1245	1246	2
I-iv-cont-mean	1246	1247	.
I-iv-cont-mean	1247	1249	09
O	1249	1250	,
B-iv-cont-mean	1251	1252	1
I-iv-cont-mean	1252	1253	.
I-iv-cont-mean	1253	1255	53
O	1256	1259	and
B-iv-cont-mean	1260	1261	1
I-iv-cont-mean	1261	1262	.
I-iv-cont-mean	1262	1264	73
I-iv-cont-mean	1265	1269	days
O	1270	1272	in
O	1273	1281	patients
O	1282	1285	who
O	1286	1294	received
O	1295	1308	pegfilgrastim
O	1309	1311	60
O	1311	1312	,
O	1313	1316	100
O	1317	1320	and
O	1321	1324	120
O	1325	1326	µ
O	1326	1327	g
O	1327	1328	/
O	1328	1330	kg
O	1330	1331	/
O	1331	1336	cycle
O	1336	1337	,
O	1338	1350	respectively
O	1350	1351	,
O	1352	1355	and
B-cv-cont-mean	1356	1357	1
I-cv-cont-mean	1357	1358	.
I-cv-cont-mean	1358	1360	69
I-cv-cont-mean	1361	1365	days
O	1366	1368	in
O	1369	1377	patients
O	1378	1381	who
O	1382	1390	received
O	1391	1392	5
O	1393	1394	µ
O	1394	1395	g
O	1395	1396	/
O	1396	1398	kg
O	1398	1399	/
O	1399	1402	day
O	1403	1413	filgrastim
O	1414	1415	(
O	1415	1416	P
O	1417	1418	=
O	1419	1420	0
O	1420	1421	.
O	1421	1424	043
O	1424	1425	)
O	1425	1426	.

O	1427	1430	The
B-outcome	1431	1440	incidence
I-outcome	1441	1443	of
I-outcome	1444	1449	grade
I-outcome	1450	1451	3
I-outcome	1451	1452	+
I-outcome	1453	1464	neutropenia
O	1465	1468	was
B-iv-bin-percent	1469	1471	76
O	1471	1472	,
B-iv-bin-percent	1473	1475	83
O	1476	1479	and
B-iv-bin-percent	1480	1482	74
I-iv-bin-percent	1483	1484	%
O	1485	1488	for
O	1489	1494	doses
O	1495	1497	of
O	1498	1511	pegfilgrastim
O	1512	1515	and
B-iv-bin-percent	1516	1518	90
I-iv-bin-percent	1519	1520	%
O	1521	1524	for
O	1525	1535	filgrastim
O	1536	1537	(
O	1537	1538	P
O	1539	1540	=
O	1541	1542	0
O	1542	1543	.
O	1543	1546	409
O	1546	1547	)
O	1547	1548	.

O	1549	1552	The
O	1553	1560	results
O	1561	1564	for
B-outcome	1565	1572	febrile
I-outcome	1573	1584	neutropenia
O	1584	1585	,
B-outcome	1586	1590	time
I-outcome	1591	1593	to
I-outcome	1594	1604	neutrophil
I-outcome	1605	1613	recovery
O	1614	1617	and
B-outcome	1618	1628	neutrophil
I-outcome	1629	1636	profile
O	1637	1641	were
O	1642	1646	also
O	1647	1650	not
O	1651	1664	significantly
O	1665	1674	different
O	1675	1682	between
O	1683	1687	arms
O	1687	1688	.

O	1689	1692	The
B-outcome	1693	1699	safety
I-outcome	1700	1708	profiles
O	1709	1711	of
O	1712	1725	pegfilgrastim
O	1726	1729	and
O	1730	1740	filgrastim
O	1741	1745	were
O	1746	1753	similar
O	1753	1754	.

O	1755	1756	A
O	1757	1763	single
O	1764	1768	dose
O	1769	1771	of
O	1772	1775	100
O	1776	1777	µ
O	1777	1778	g
O	1778	1779	/
O	1779	1781	kg
O	1782	1786	once
O	1786	1787	-
O	1787	1790	per
O	1790	1791	-
O	1791	1796	cycle
O	1797	1811	administration
O	1812	1814	of
O	1815	1828	pegfilgrastim
O	1829	1837	provided
O	1838	1848	neutrophil
O	1849	1856	support
O	1857	1860	and
O	1861	1862	a
O	1863	1869	safety
O	1870	1877	profile
O	1878	1888	comparable
O	1889	1891	to
O	1892	1897	daily
O	1898	1910	subcutaneous
O	1911	1921	injections
O	1922	1924	of
O	1925	1935	filgrastim
O	1936	1938	in
O	1939	1946	Chinese
O	1947	1953	breast
O	1954	1960	cancer
O	1961	1969	patients
O	1970	1979	receiving
O	1980	1983	TAC
O	1984	1996	chemotherapy
O	1996	1997	.
